Weiming Pharmaceutical plans to sign a sales contract worth 53.978 million yuan
March 13, 2025
Source: drugdu
112
On March 12, Weiming Pharmaceutical announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. plans to sign a "Sales Contract" with Jiangsu Soho Innovation Technology Group Co., Ltd. to purchase the liquid storage system and chromatography system, filler and reaction bags required for the Shandong Weiming Biomedicine Industrial Park project recombinant human nerve growth factor eye drops production workshop from Jiangsu Soho. The total contract price is 53.978 million yuan. The signing of this contract provides hardware guarantee for the industrialization of the company's existing pipelines, which is conducive to further improving the company's industrial layout and promoting the continuous growth of the company's operating performance.
https://finance.eastmoney.com/a/202503133344224416.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bivalent HPV is hit hard! Wantai Biopharmaceuticals’ vaccine volume and price both fell, betting on nine-valent may become the last trump card May 30, 2025
- The United States will no longer recommend routine COVID-19 vaccinations for healthy children and pregnant women May 30, 2025
- Kangtai Biological’s trivalent influenza vaccine clinical trial application accepted May 30, 2025
- Fosun Pharma’s self-developed MEK inhibitor has been approved for marketing in China. This drug can treat related rare blood tumors May 30, 2025
- The company’s products have obtained medical device registration certificates May 29, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
